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Abstract
Congenital bilateral absence of the vas deferens (CBAVD) is a monosymptomatic disease confined to the male reproductive
system with similarity to the phenotype of cystic fibrosis (CF), and mutations in the CFTR gene are highly prevalent in Caucasian
CBAVD patients. While CF is very rare in Japan, CBAVD is not. Our previous study demonstrated high prevalence of the 5T
allele in the CFTR gene in Japanese CBAVD patients. We analyzed whole exons of the CFTR gene in 19 CBAVD patients and
53 normal individuals using polymerase chain reaction amplification-single strand conformation polymorphism analysis and direct
sequencing. Three missense mutations (W216X, G1349S, Q1352H) were found in seven CFTR alleles, and the 5T allele was
positive in 11 of 38 CFTR patient alleles. Consequently, 47% of CFTR chromosomes in the patients were affected, and 11
individuals (58%) had at least one mutated CFTR allele. In contrast, three of 53 normal individuals (5.7%) had a missense
mutation in one of the CFTR genes, but no 5T allele was detected (both P-0.0001). Mutations of the CFTR gene are closely
associated with Japanese patients with CBAVD.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
Keywords: Cystic fibrosis; 5T allele; Male reproductive system; Single-strand conformation polymorphism analysis; Direct sequencing
1. Introduction
Congenital bilateral absence of the vas deferens
(CBAVD) accounts for approximately 6% of cases of
obstructive azoospermia w1x and is responsible for 1%
of male infertility w2x. It is well known that CBAVD is
also present in approximately 95% of male patients with
cystic fibrosis (CF), which is a disease of exocrine
organs characterized by chronic sinusitis, severe obstruc-
tive respiratory impairment, pancreatic exocrine insuffi-
ciency and elevated concentrations of sweat electrolytes
w3x.
CF is caused by mutations of the gene coding for
cystic fibrosis transmembrane conductance regulator
(CFTR) w3–5x. To date, more than 1000 pathogenic
CFTR (ABCC7) gene mutations have been reported
worldwide w6,7x. Mutations of the CFTR gene have also
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been frequently identified in patients with CBAVD w8–
13x. In particular, the 5T allele in intron 8 of the gene,
which causes reduced levels of normal CFTR mRNA
w14x, has significant clinical effects related to male
infertility w15x. These observations strongly suggest that
CBAVD is one of the monosymptomatic diseases with
CFTR etiology w16x, which has only genital presenta-
tions of the classical form of CF.
In Caucasians, a carrier frequency of mutations of the
CFTR gene is estimated as approximately 1 in 25, and
an incidence of the disease is 1 in 2500 live births w3,6x.
In contrast, CF had been believed to be rare in the
Asian or Oriental populations w3,6,17x. Thus far, approx-
imately 130 typical cases of CF have been reported in
Japan w18–22x, and the incidence was estimated as
approximately 1 in 100 000–350 000 live births w18x.
Interestingly enough, however, CBAVD itself is not
uncommon in Japan, with an estimated prevalence of
1% in male infertile patients, which is comparative with
that previously reported in the United States w1,2x. Our
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Table 1
CFTR gene mutations in 19 male patients with CBAVD
Patient Age at study CFTR genotype (TG)mTn genotype
number (years)
1 41 G1349SyQ1352H (TG)11T7y(TG)11T7
2 31 W216XyQ1352H (TG)11T7y(TG)11T7
3 29 Q1352HyWT (TG)11T7y(TG)13T5
4 29 Q1352HyWT (TG)11T7y(TG)13T5
5 42 Q1352HyWT (TG)11T7y(TG)13T5
6 29 WTyWT (TG)13T5y(TG)13T5
7 29 WTyWT (TG)13T5y(TG)13T5
8 36 WTyWT (TG)13T5y(TG)12T7
9 36 WTyWT (TG)13T5y(TG)12T7
10 32 WTyWT (TG)13T5y(TG)11T7
11 29 WTyWT (TG)12T5y(TG)12T7
12 35 WTyWT (TG)12T7y(TG)12T7
13 34 WTyWT (TG)12T7y(TG)12T7
14 26 WTyWT (TG)12T7y(TG)12T7
15 29 WTyWT (TG)12T7y(TG)12T7
16 34 WTyWT (TG)12T7y(TG)12T7
17 32 WTyWT (TG)12T7y(TG)11T7
18 31 WTyWT (TG)11T7y(TG)11T7
19 48 WTyWT (TG)11T7y(TG)11T7
WT denotes wild type in which mutations with a codon or alter-
native splicing were all negative.
previous study has shown that any of 32 or 70 frequent
mutations observed in CF patients in North America
was not present, but the allelic frequency of the 5T
variant was 30%, as observed in Caucasians CBAVD
patients w23x. Importantly, analyses for CF in Japan have
identified several quite novel or extremely rare mutations
in the CFTR gene w19–22x.
To elucidate further the molecular basis of CBAVD
in Japan, we have analyzed the whole 27 exons and the
59- and 39- intron–exon boundaries of the CFTR gene,
as well as the genotype of TG-repeat and polythymidine
tract w(TG)mTnx in intron 8 in patients with this disease
in the present study. Our data clearly demonstrate the
close association of CFTR gene mutations and CBAVD
in the Japanese population.
2. Materials and methods
2.1. Subjects for study
We have analyzed the CFTR genotype in 19 male
Japanese individuals with CBAVD after obtaining
informed consent. Their age ranged from 26 to 48 years
(average 33.3"5.5) at the time of the study (Table 1).
A total of 10 individuals were also subjects in the
previous study w23x. No patient was reported to have
pulmonary or gastrointestinal manifestations of typical
CF, and four individuals tested for sweat chloride levels
showed normal results. The diagnosis of CBAVD was
made on the basis of scrotal exploration, analysis of
semen, such as volume, number and concentration of
sperm, and transrectal and abdominal ultrasonography
w23x. As control, 53 normal individuals were also eval-
uated for CFTR gene mutations.
2.2. Analyses of CFTR gene mutations
Genomic DNA was isolated from nucleated blood
cells using a commercially available DNA extraction kit
(Qiagen, Tokyo, Japan). First, all 27 exons of the CFTR
gene including both the 59- and 39- intron–exon junctions
were subjected to single-strand conformation polymor-
phism (SSCP) analysis w24x. DNA from CBAVD
patients or normal individuals was amplified by poly-
merase chain reaction (PCR) with specific sets of
primers as described elsewhere w25x, and the PCR
products of each exon were electrophoresed on GeneGel
Excel 12.5y24 (Pharmacia Biotech, Tokyo, Japan) and
evaluated by silver staining. Those individuals whose
PCR products showed different mobility from those of
the reference control were forwarded to further evalua-
tion by direct sequencing using the dideoxy chain-
terminating method (Pharmacia Biotech, Tokyo, Japan)
w25x. Once any mutation was detected, its eligibility was
further confirmed by additional PCR amplification with
the mutant allele-specific primer sets in patients, as well
as in the normal control subjects.
Second, the (TG)mTn polymorphism at the splice
acceptor site in intron 8 was evaluated w14,26x. The
region containing the intron 8–exon 9 junction and exon
9 was PCR-amplified with primers CF9iS2 (59-
CATAAAACAAGCATCTATTG-39) and CF9iAS2 (59-
AGAGACATGGACACCAAATT-39), and was subjected
to direct sequencing as described above w25x.
All data were expressed as mean"standard deviation.
The chi-square statistics with Yates’ correction were
used appropriately. P values of less than 0.05 were
considered to be of statistical significance.
3. Results
Using PCR-SSCP analysis followed by direct
sequencing, we could detect three missense mutations
in a total of seven CFTR alleles: W216X (779G™A)
in exon 6a; G1349S (4177G™A); and Q1352H
(4188G™C) in exon 22 (Table 1). Q1352H mutation
was the most frequent one detected in as many as five
individuals with the disease. W216X and G1349S were
novel mutations and have been deposited in the CF
database w7x. The presence of these missense mutations
in patients was further verified by separate PCR ampli-
fication with sets of allele-specific oligonucleotide prim-
ers at the more stringent hybridization (data not shown).
In contrast, in 53 normal individuals similarly tested,
E217G was found in one chromosome and Q1352H was
in two, but no other mutations were detected (data not
shown). These individuals were totally free from clinical
symptoms of CF. The frequency of codon mutations was
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Table 2




Mutation causing codon change 7y38 (18.4%) 3y106 (2.8%) 0.0041
5T variant 11y38 (28.9%) 0y106 (0%) -0.0001
Abnormal CFTR allele including 5T variant 18y38 (47.4%) 3y106 (2.8%) -0.0001
Individuals with at least one affected CFTR allele 11y19 (57.9%) 3y53 (5.7%) -0.0001
significantly higher in the patients with CBAVD than in
the normal control subjects (Ps0.0041) (Table 2).
Evaluation of the (TG)mTn polymorphism of intron
8 in Japanese patients with CBAVD demonstrated that
(TG)13T5 was present in 10 alleles, (TG)12T5 in one,
(TG)12T7 in 14 and (TG)11T7 in 13 (Table 1).
Therefore, the allelic frequency of 5T was 28.9% in
individuals with CBAVD (Tables 1 and 2). In contrast,
the 5T allele was not detected in any of the 106 CFTR
alleles of the normal subjects (P-0.0001).
Importantly, including the 5T allele, 18 CFTR alleles
(47.4%) were affected in CBAVD individuals, and a
total of 11 patients with the disease (57.9%) had at least
one mutated allele (Tables 1 and 2). In particular, five
patients were compound heterozygotes: patient 1 was
associated with G1349S and Q1352H, patient 2 with
W216X and Q1352H, and patients 3, 4 and 5 with
Q1352H and 5T. In addition, two were homozygotes of
the 5T allele (patients 6 and 7) (Table 1). In marked
contrast, only three out of 106 alleles (2.8%) or 53
individuals (5.7%) in the normal population were affect-
ed as described above. Both the prevalence of the
mutated alleles and the number of individuals positive
for at least one abnormal CFTR gene were significantly
higher in the patients with CBAVD than in the normal
control subjects (both P-0.0001) (Table 2).
4. Discussion
The prevalence of CBAVD in Japan is estimated as
approximately 1% in male infertile patients, which is
compatible with the level observed in the United States
w1,2x. Besides a high prevalence of absent or rudimen-
tary vas deference in individuals with CF, CBAVD by
itself is now considered to be one of the monosympto-
matic diseases with CFTR etiology confined to the male
reproductive system w16x. CF, the most common lethal
autosomal recessive disease in the Caucasian population,
is caused by mutations of the CFTR gene, and to date
more than 1000 mutations have been reported worldwide
to be responsible for developing clinical manifestations
of CF w6,7x. Likewise, a large number of reports have
described strong association between CBAVD and CFTR
mutations in Caucasians w8–13x
The most frequent CFTR gene alteration identified in
Caucasian individuals with CBAVD is the 5T variant in
the intron 8 polythymidine tract w15x. This splicing
variant, along with the preceding higher repetitive din-
ucleotide TG sequences such as (TG)13 or (TG)12,
produces more mRNA transcripts with inframed deletion
of exon 9 w14,26,27x. The exon 9 mRNA results iny
synthesis of non-functional CFTR protein. The particular
combination of the two CFTR alleles in a given individ-
ual (i.e. the genotype) results in specific levels of normal
CFTR mRNA and in a specific clinical phenotype.
When both CFTR genes have the 5T allele, this non-
functional CFTR mRNA accounts for up to 92% of the
total mRNA w14x. In general, a small amount of normal
CFTR protein could prevent clinical manifestations of
CF in the lungs or pancreas. However, a high level of
CFTR gene expression in epithelial cells is required in
the fetus for normal development of male genital organs,
such as the epididymal gland and the vas deferens
w28,29x. This is the presumed pathogenesis by which
individuals with subtle abnormalities in the CFTR gene
such as the 5T variant would have errors in development
of the reproductive system, resulting in CBAVD without
any typical clinical manifestation of CF w23x.
In the present study, we have found that a significant
proportion, as high as 30%, of Japanese males with
CBAVD have the 5T allele, as was observed in Cauca-
sian CBAVD patients w15x. In contrast, no 5T variant
was detected among the normal control population. In
this context, the 5T allele is also likely a disease-causing
mutation in CBAVD in Japan. Furthermore, although
our previous evaluation failed to detect any of 32 or 70
frequent mutations responsible for more than 90% of
Caucasian CF patients in North America w30x, by thor-
ough analysis over all the 27 coding exons along with
the 59- and 39- adjunct sequences, this study demonstrat-
ed that five patients had at least one codon mutation in
their CFTR genes. Among the mutations found in
CBAVD patients, G1349S and W216X are quite novel
and which we deposited in the CF database in 1999 w7x.
Another mutation, Q1352H, which was previously
described by other Japanese investigators w7x, is likely
the most prevalent alteration in Japan. The 1352nd
amino acid residue is coded by trinucleotide in exon 22
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of the CFTR gene, and is located in the second ATP-
binding domain. Thus, it is speculated that alteration of
the codon for glutamine to histidine would cause
decreased efficiency in activation of the CFTR Cly
channel. Furthermore, it should be determined in the
future whether or not this common Q1352H CF allele
might be associated with other types of ‘CFTRpathies’
including the classical form of CF in the Japanese
population w16x.
Most importantly, we have demonstrated that 47% of
CFTR chromosomes of the Japanese patients with
CBAVD were affected, and 11 patients (58%) had at
least one mutated CFTR allele. As observed in Cauca-
sian CBAVD patients, mutations of the CFTR gene
including the 5T allele were closely associated with
CBAVD in the Japanese population. The prevalence of
CFTR gene mutations seems to be much higher in the
Japanese population than previously estimated w18x. This
may be true, since three normal individuals had one
mutated CFTR allele, two of which were Q1352H, as
stated above. Interestingly enough, the profile of gene
mutations in the Japanese population is likely quite
distinct from that of the Caucasian counterpart w6x. In
this regard, the screening system designed for CFTR
mutations in Caucasians failed to detect any abnormal
allele in the Japanese patients with CBAVD, as for CF
w21,22x.
However, we could not detect any CFTR mutation in
the remaining eight patients (42%). This might be
because of the SSCP method, since this approach is not
foolproof for screening CFTR mutations and has its
limitations in sensitivity, as well as in the capability of
detecting mutations in general w24x. Moreover, it is
suggested that Japanese may have uncharacterized muta-
tions in CF alleles located in the intervening sequences,
or that another gene could be associated with CBAVD.
Further study is needed to demonstrate the more detailed
profile of CFTR gene mutations in Japanese individuals
with CBAVD. Moreover, sterility in patients with
CBAVD can now be treated by modern assisted repro-
duction technology w23x. If the female partner is a
heterozygous carrier of a CF mutation, their offspring
might have the possibility of inheriting a currently
undetected genetic defect and developing clinical man-
ifestations of CF andyor CBAVD w16x. Therefore, all
couples should be informed of this possibility and the
importance of genetic testing for CFTR gene mutations
in advance of intracytoplasmic sperm injection w16,23x.
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